151 results on '"Zin, A"'
Search Results
2. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Htut, Thura Win, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Win, Myint Aung, additional, Phyu, Ei Moe, additional, and Oo, Thein H., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
- Author
-
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, and Thein H. Oo
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
4. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
- Author
-
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, and Thein H. Oo
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
5. Efficacy and Tolerability of Luspatercept in Patients with Lower Risk Myelodysplastic Syndrome and Anemia: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
- Author
-
Htut, Thura Win, Phyu, Ei Moe, Zaw, Myo Htet, Myat, Yin Mon, and Thein, Kyaw Zin
- Published
- 2023
- Full Text
- View/download PDF
6. Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
- Author
-
Swarup, Sriman, primary, Quick, Donald P., primary, Sultan, Anita, primary, Win, Myint Aung, primary, Phyu, Ei Moe, primary, Htut, Thura Win, primary, Wongsaengsak, Sariya, primary, Zin, Myet Mon, primary, Han, Myat Min, primary, Myat, Yin Mon, primary, Awasthi, Sanjay, primary, Tijani, Lukman, primary, and Thein, Kyaw Zin, primary
- Published
- 2019
- Full Text
- View/download PDF
7. Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
- Author
-
Htut, Thura Win, primary, Win, Myint Aung, additional, Swarup, Sriman, additional, Sultan, Anita, additional, Adhikari, Nimesh, additional, Phyu, Ei Moe, additional, Dash, Akshar, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Awasthi, Sanjay, additional, Tijani, Lukman, additional, D'Cunha, Nicholas, additional, Quick, Donald P., additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab
- Author
-
Htut, Thura Win, primary, Tun, Aung M, additional, Sultan, Anita, additional, Win, Myint Aung, additional, Swarup, Sriman, additional, Phyu, Ei Moe, additional, Hlaing, Pwint Phyu, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Hardwicke, Fred, additional, Quick, Donald P., additional, D'Cunha, Nicholas, additional, Tijani, Lukman, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib
- Author
-
Swarup, Sriman, primary, Sultan, Anita, additional, Tijani, Lukman, additional, Htut, Thura Win, additional, D'Cunha, Nicholas, additional, Wongsaengsak, Sariya, additional, Quick, Donald P., additional, Htwe, Khaing Khaing, additional, Hlaing, Pwint Phyu, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Dash, Akshar, additional, Hardwicke, Fred, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails
- Author
-
Wongsaengsak, Sariya, primary, Ball, Somedeb, additional, Khandelwal, Nuvneet, additional, Tikue, Alay, additional, Motes, Arunee, additional, Jahan, Nusrat, additional, Thein, Kyaw Zin, additional, and Tijani, Lukman, additional
- Published
- 2019
- Full Text
- View/download PDF
11. Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen
- Author
-
Htut, Thura Win, primary, Quick, Donald P., additional, Win, Myint Aung, additional, Swarup, Sriman, additional, Sultan, Anita, additional, Ball, Somedeb, additional, Phyu, Ei Moe, additional, Yu, Nyein Htway, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Hardwicke, Fred, additional, D'Cunha, Nicholas, additional, Awasthi, Sanjay, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
12. Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma
- Author
-
Thein, Kyaw Zin, primary, Htut, Thura Win, additional, Win, Myint Aung, additional, Swarup, Sriman, additional, Sultan, Anita, additional, Ball, Somedeb, additional, Phyu, Ei Moe, additional, Tun, Aung M, additional, Pandey, Ramesh, additional, Han, Myat Min, additional, Hardwicke, Fred, additional, Tijani, Lukman, additional, D'Cunha, Nicholas, additional, and Quick, Donald P., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Tijani, Lukman, additional, and Oo, Thein H., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib
- Author
-
Graf, Chandler, primary, Sultan, Anita, additional, Quick, Donald P., additional, Grant, Bradley J., additional, Swarup, Sriman, additional, Htut, Thura Win, additional, Hlaing, Pwint Phyu, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Hardwicke, Fred, additional, Awasthi, Sanjay, additional, D'Cunha, Nicholas, additional, Tijani, Lukman, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
15. A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Quick, Donald P., additional, and Oo, Thein Hlaing, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib
- Author
-
Kopel, Jonathan, primary, Swarup, Sriman, additional, Sultan, Anita, additional, Tijani, Lukman, additional, Phyu, Ei Moe, additional, Win, Myint Aung, additional, Htut, Thura Win, additional, Aung, Ye, additional, Dash, Akshar, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Quick, Donald P., additional, D'Cunha, Nicholas, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials
- Author
-
Htut, Thura Win, primary, Thein, Kyaw Zin, additional, Sultan, Anita, additional, Swarup, Sriman, additional, Win, Myint Aung, additional, Phyu, Ei Moe, additional, Awasthi, Sanjay, additional, Dash, Akshar, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Hardwicke, Fred, additional, Tijani, Lukman, additional, D'Cunha, Nicholas, additional, and Quick, Donald P., additional
- Published
- 2019
- Full Text
- View/download PDF
18. Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Tijani, Lukman, additional, and Oo, Thein H., additional
- Published
- 2019
- Full Text
- View/download PDF
19. Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution Experience
- Author
-
Swarup, Sriman, primary, Ball, Somedeb, additional, Adhikari, Nimesh, additional, Sultan, Anita, additional, Swarup, Khatrina, additional, Thein, Kyaw Zin, additional, Quirch, Miguel, additional, Tijani, Lukman, additional, and Awasthi, Sanjay, additional
- Published
- 2019
- Full Text
- View/download PDF
20. Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials
- Author
-
Swarup, Sriman, primary, Quick, Donald P., additional, Sultan, Anita, additional, D'Cunha, Nicholas, additional, Htut, Thura Win, additional, Hlaing, Pwint Phyu, additional, Sharma, Upama, additional, Adhikari, Nimesh, additional, Aung, Ye, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Hardwicke, Fred, additional, Tijani, Lukman, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
- Author
-
Sultan, Anita, primary, Grant, Bradley J., additional, Quick, Donald P., additional, Graf, Chandler, additional, Swarup, Sriman, additional, Kopel, Jonathan, additional, Htut, Thura Win, additional, Ball, Somedeb, additional, Phyu, Ei Moe, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, D'Cunha, Nicholas, additional, Win, Myint Aung, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
22. Effective Implementation of a Structured Protocol for Facilitation of the Judicious Use of Antibody Test for Diagnosis of Heparin Induced Thrombocytopenia
- Author
-
Ball, Somedeb, primary, Adhikari, Nimesh, additional, Sultan, Anita, additional, Thein, Kyaw Zin, additional, Swarup, Khatrina, additional, Srikala, Meda, additional, Duffo, Francis Mogollon, additional, Rehman, Shabnam, additional, Tijani, Lukman, additional, and Swarup, Sriman, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
- Author
-
Grant, Bradley J., primary, Sultan, Anita, additional, D'Cunha, Nicholas, additional, Graf, Chandler, additional, Swarup, Sriman, additional, Win, Myint Aung, additional, Phyu, Ei Moe, additional, Htut, Thura Win, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Adhikari, Nimesh, additional, Yu, Nyein Htway, additional, Quick, Donald P., additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
24. Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials
- Author
-
Sultan, Anita, primary, Graf, Chandler, additional, Quick, Donald P., additional, Swarup, Sriman, additional, Kopel, Jonathan, additional, Htut, Thura Win, additional, Adhikari, Nimesh, additional, Han, Myat Min, additional, Myat, Yin Mon, additional, Awasthi, Sanjay, additional, Tijani, Lukman, additional, D'Cunha, Nicholas, additional, and Thein, Kyaw Zin, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Quick, Donald P., additional, and Oo, Thein H., additional
- Published
- 2019
- Full Text
- View/download PDF
26. Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
- Author
-
Thura Win Htut, Sariya Wongsaengsak, Yin Mon Myat, Donald P. Quick, Ei Moe Phyu, Lukman Tijani, Anita Sultan, Sriman Swarup, Kyaw Zin Thein, Myint Aung Win, Myat Min Han, Sanjay Awasthi, and Myet Mon Mon Zin
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Ofatumumab ,Biochemistry ,Gastroenterology ,Sepsis ,chemistry.chemical_compound ,Pneumonia ,chemistry ,Internal medicine ,medicine ,Rituximab ,Refractory Chronic Lymphocytic Leukemia ,Idelalisib ,business ,Adverse effect ,Pneumonitis ,medicine.drug - Abstract
Introduction: Phosphatidylinositol 3-kinase (PI3K) is a kinase protein involved in downstream signaling for multiple pathways in B cells and is important for B cell survival, proliferation and metabolism. Hence, PI3K inhibitors have become an attractive therapeutic option for treatment of B cell malignancies. Two prominent PI3K inhibitors, (PI3Kδ-selective inhibitor) and duvelisib (PI3Kδ/γ-combinatorial inhibitor), are currently being studied in relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and have shown to improve survival in recent trials with notable toxicities. We analyzed phase 3 trials to assess the incidence of serious adverse events, pneumonitis, infection and sepsis associated with PI3K inhibitors in this susceptible population. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase 3 RCTs utilizing PI3K inhibitors in patients with relapsed and refractory CLL/SLL that mention serious adverse events, pneumonitis, infection and sepsis as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: Four phase 3 RCTs with a total of 1,216 patients with relapsed and refractory CLL/SLL were included in analysis. Studies compared ofatumumab vs idelalisib+ofatumumab, rituximab vs idelalisib+rituximab, bendamustine+ rituximab vs idelalisib+bendamustine+rituximab and ofatumumab vs duvelisib. The randomization ratio was 2:1 in Jones et al. study and 1:1 in other studies. The I2 statistic for heterogeneity was 49, suggesting some heterogeneity among RCTs. The incidence of serious adverse events was 479 (73.69%) in study group vs 252 (44.92%) in control group (RR, 1.58; 95% CI: 1.37 - 1.83; P < 0.0001 and RD, 0.26; 95% CI: 0.13 - 0.40; P = 0.0002). Pneumonitis was noted in 20 (3.07%) vs 1 (0.18%) in control group with RR of 6.53 (95% CI: 1.74 -24.53; P = 0.005) and RD of 0.02 (95% CI: 0.01 - 0.04; P = 0.0004). The incidence of any-grade pneumonia was 107 (16.46%) in study group vs 54 (9.63%) in control group (RR, 1.61; 95% CI: 1.00 - 2.58; P = 0.05). High-grade pneumonia was reported in 81 (12.46%) in idelalisib arm versus 35 (6.24%) in control group with RR of 1.84 (95% CI: 0.82 - 4.13; P = 0.14). Pneumocystis jiroveci pneumonia (PJP) rate was 2.24% higher in study group compared to control arm (RR, 3.87; 95% CI: 1.22 - 12.29; P = 0.02). Any-grade upper respiratory tract infection (URTI) was 14% in study group versus 7.84% in control arm (RR, 1.65; 95% CI: 1.17 - 2.34; P = 0.005). Sepsis rate was 2.88% higher in idelalisib group compared to control arm and the pooled RR was statistically significant at 2.68 (95% CI: 1.19 - 6.04, P = 0.02). Treatment-related deaths were 64 (11.85%) in study arm vs 28 (6.17%) in control arm according to analysis of 3 trials. The pooled RR was also statistically significant at 1.87 (95% CI: 1.21 -2.88; P = 0.005). Conclusions: Our meta-analysis showed that the incidence of serious adverse events, pneumonitis, PJP pneumonia, any-grade URTI and sepsis was significantly higher in PI3K inhibitors group with RR of 1.58 for serious adverse events, RR of 6.53 for pneumonitis, RR of 3.87 for PJP pneumonia and RR of 2.68 for sepsis respectively. Moreover, patients on PI3K inhibitors experienced 5.68% higher incidence of treatment-related deaths with RR of 1.87, compared to control arm. Since treatment-related serious toxicities and deaths are higher amongst patients treated with these agents, extra caution should be observed and recommended with their use. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
27. A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy
- Author
-
Donald P. Quick, Kyaw Zin Thein, and Thein Hlaing Oo
- Subjects
Relative risk reduction ,Rivaroxaban ,medicine.medical_specialty ,business.industry ,Immunology ,Absolute risk reduction ,Cell Biology ,Hematology ,Biochemistry ,Chemotherapy regimen ,law.invention ,Randomized controlled trial ,law ,Relative risk ,Meta-analysis ,Internal medicine ,Number needed to treat ,Medicine ,business ,medicine.drug - Abstract
Introduction: PATP in solid cancer patients remains uncertain and is not routinely recommended although thrombosis is shown to be the second leading cause of death in cancer patients. Many studies failed to demonstrate in solid cancer outpatients improvement in overall survival despite decreasing venous thromboembolism (VTE) rates by PATP. We conducted a systematic review and meta-analysis of RCTs to determine the benefit and risk of PATP with low-molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) in patients with gastrointestinal cancers receiving chemotherapy. Methods: We performed a comprehensive literature search using MEDLINE and EMBASE databases through June 30, 2019. The references of all potential studies were also reviewed for any additional relevant studies. The RCTs with reduction in VTE as a primary or secondary endpoint and the major bleeding (MB) as a safety outcome were incorporated in the analysis. The primary meta- analytic approach was a fixed effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Results: A total of 1,932 patients with gastric, gastroesophageal junctional (GEJ) and colorectal cancers from a subgroup of three RCTs were included in our meta-analysis. The prophylactic doses of LMWHs and DOAC (rivaroxaban) were used in the studies. The duration of LMWH and DOAC ranged from 3 to 6 months. The randomization ratio was 2 to 1 in PROTECHT study and 1 to 1 in all other studies. The I2 statistic for heterogeneity was 0, suggesting homogeneity among RCTs. The VTE incidence was 13 (1.26%) in PATP group and 23 (2.55%) in control group with a RR of 0.49 (95% CI: 0.25 to 0.96, P = 0.04). The absolute RD in VTE was -0.01 (95% CI: -0.03 to -0.00, P 0.04) with an estimate of the number needed to treat (NNT) of 78 to prevent one VTE event. In a subset of patients with gastric and GEJ cancers (n=587), the VTE incidence was 4 (1.37%) in PATP group and 10 (3.40%) in control group with a RR of 0.40 (95% CI: 0.13 to 1.24, P = 0.11). Conclusions: In our study, the relative risk reduction is 48% with a NNT of 78 to prevent one VTE in ambulatory patients with gastrointestinal cancers. Nevertheless, there is no statistically significant reduction in VTE events in a subset of gastric and GEJ cancers which are considered high risk in Khorana score. Based on the findings, PATP is not recommended in patients with gastrointestinal cancers on chemotherapy at this time. Further studies are necessary to define high risk subsets of gastrointestinal cancer patients receiving chemotherapy who may benefit from PATP. Disclosures Oo: Medical Education Speakers Network: Honoraria; Janssen and Janssen: Other: site co-investigator.
- Published
- 2019
28. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
- Author
-
Ei Moe Phyu, Anita Sultan, Thura Win Htut, Sriman Swarup, Nyein Htway Yu, Myat Min Han, Bradley J. Grant, Kyaw Zin Thein, Nimesh Adhikari, Myint Aung Win, Nicholas D'Cunha, Yin Mon Myat, Chandler Graf, and Donald P. Quick
- Subjects
Bendamustine ,Oncology ,medicine.medical_specialty ,business.industry ,Chronic lymphocytic leukemia ,Immunology ,Cell Biology ,Hematology ,Neutropenia ,Ofatumumab ,medicine.disease ,Biochemistry ,Duvelisib ,chemistry.chemical_compound ,chemistry ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Refractory Chronic Lymphocytic Leukemia ,Idelalisib ,business ,Febrile neutropenia ,medicine.drug - Abstract
Introduction: Chronic lymphocytic leukemia is the most prevalent adult leukemia in western countries. Phosphatidylinositol 3-kinase (PI3K) is a kinase protein involved in downstream signaling for the B-cell receptor signaling pathway and has been shown to involve in the pathogenesis of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/ SLL) by promoting B-cell survival, proliferation and metabolism. Two prominent PI3K inhibitors, idelalisib (PI3Kδ-selective inhibitor) and duvelisib (PI3Kδ/γ-combinatorial inhibitor), have recently shown to improve survival in patients with relapsed and refractory CLL/ SLL. We undertook a systematic review and meta-analysis of phase 3 randomized controlled trials to determine the risk of hematological toxicities associated with PI3K inhibitors. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase 3 RCTs utilizing PI3K inhibitors in patients with relapsed and refractory CLL/SLL that mention hematological toxicities as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: Four phase 3 RCTs with a total of 1,216 patients with relapsed and refractory CLL/SLL were included. Studies compared ofatumumab vs idelalisib+ofatumumab, rituximab vs idelalisib+rituximab, bendamustine+ rituximab vs idelalisib+bendamustine+rituximab and ofatumumab vs duvelisib. The randomization ratio was 2:1 in Jones et al. study and 1:1 in other studies. The I2 statistic for heterogeneity was 49, suggesting some heterogeneity among RCTs. The RR of all-grade side effects were as follows: anemia, 1.39 (95% CI: 0.89 - 2.17; p = 0.15); neutropenia, 1.33 (95% CI: 1.06 - 1.67; p = 0.02); and thrombocytopenia, 1.23 (95% CI: 0.69 - 2.18; p = 0.48). The RR of high-grade adverse effects were as follows: anemia, 1.29 (95% CI: 0.62 - 2.67, p = 0.50); neutropenia, 1.51 (95% CI: 1.22 - 1.88; p = 0.0001); and thrombocytopenia, 1.21 (95% CI: 0.66 - 2.22; p = 0.53). The incidence of febrile neutropenia was 76 (11.69%) in study group vs 22 (3.92%) in control group with RR of 2.62 (95% CI: 1.27 -5.41, P = 0.009). Conclusions: PI3K inhibitors, idelalisib (PI3Kδ-selective inhibitor) and duvelisib (PI3Kδ/γ-combinatorial inhibitor), increased the risk of all grades of neutropenia and febrile neutropenia, with RR of 2.62 for febrile neutropenia, in patients with relapsed and refractory CLL/SLL. Vigilant monitoring is warranted, and proper supportive care and dose modifications should be followed. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
29. Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma
- Author
-
Thura Win Htut, Somedeb Ball, Myat Min Han, Ei Moe Phyu, Myint Aung Win, Anita Sultan, Donald P. Quick, Nicholas D'Cunha, Lukman Tijani, Kyaw Zin Thein, Ramesh Kumar Pandey, Aung M. Tun, Sriman Swarup, and Fred Hardwicke
- Subjects
Oncology ,medicine.medical_specialty ,Bortezomib ,business.industry ,Immunology ,Daratumumab ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Thalidomide ,Transplantation ,Regimen ,Prednisone ,Internal medicine ,medicine ,business ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Introduction: Management of newly diagnosed multiple myeloma (NDMM), which accounts for 1% of all cancers, is an area in dire need of therapeutic innovation. In recent years, the introduction of novel agents is one of the major advances in the management of patients with NDMM, in both transplant- eligible and transplant- ineligible candidates. Studies have combined daratumumab, a human IgGκ monoclonal antibody that targets CD38 which is highly expressed on myeloma cells, with proteasome inhibitors and immunomodulatory agents-based regimens in the first-line treatment of NDMM. The purpose of our study is to explore and consolidate the efficacy of upfront daratumumab combination regimen in patients with NDMM. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing daratumumab in patients with newly diagnosed/ untreated multiple myeloma were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for progression-free survival (PFS) with 95% confidence interval (CI). Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) for overall response rate (ORR), including stringent complete response (sCR), CR and very good partial response (VGPR). Heterogeneity was assessed with Cochran's Q -statistic. Random effects model was applied. Results: Three phase III RCTs with a total of 2,528 patients with NDMMwere included.Studies compared daratumumab (D) + bortezomib (V) + melphan (M) + prednisone (P) vs VMP, D + lenalidomide (R) + dexamethasone (d) vs Rd, and DVd + thalidomide (T) vs VTd. The randomization ratio was 1:1 in all studies. The I2statistic for heterogeneity was 0, suggesting homogeneity among RCT. The pooled HR for PFS was statistically significant at 0.52 (95% CI: 0.44-0.61; P < 0.0001). The PFS benefit was observed in all ISS categories, types of immunoglobulin (Ig) and standard risk cytogenetic; ISS I cohort (HR, 0.55; 95% CI: 0.37- 0.82; P = 0.003), ISS II cohort (HR, 0.43; 95% CI: 0.33- 0.55; P < 0.0001), ISS III cohort (HR, 0.63; 95% CI: 0.48- 0.82; P = 0.0006), IgG cohort (HR, 0.56; 95% CI: 0.40- 0.77; P = 0.0003), non-IgG cohort (HR, 0.52; 95% CI: 0.28- 0.97; P = 0.04), and standard risk cytogenetic cohort (HR, 0.43; 95% CI: 0.35- 0.53; P < 0.0001). The pooled HR for PFS in high risk cytogenetic cohort was not statistically significant at 0.76 (95% CI: 0.53- 1.10; P = 0.15). The pooled RR for ORR was 1.13 (95% CI: 1.01-1.26; P = 0.03), sCR was 2.02 (95% CI: 1.33-3.08; P = 0.001), CR was 1.46 (95% CI: 1.20-1.79; P = 0.0002),and VGPR was 1.01 (95% CI: 0.82-1.25; P = 0.93). The pooled RR for negative minimal residual disease (MRD) was 2.54 (95% CI: 1.24-5.20; P = 0.01). Conclusions: Upfront combination regimen with daratumumab significantly improved PFS, ORR, sCR and CR along with negative MRD, compared to control arm in patients with NDMM. The improvement in PFS was noted across all subgroups except in high-risk cytogenetic group. More randomized studies are required to explore further novel agents and to formulate optimal combination regimen to improve survival in this high-risk cytogenetic subset. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
30. Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy
- Author
-
Kyaw Zin Thein, Lukman Tijani, and Thein Hlaing Oo
- Subjects
Oncology ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Immunology ,Hazard ratio ,Cancer ,Low molecular weight heparin ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,Confidence interval ,Metastasis ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,business ,Lung cancer - Abstract
Introduction: LC is the leading cause of cancer mortality in USA. PATP was provided in experimental trials to decrease the venous thromboembolism (VTE) rates and to provide anti-tumor effect with ultimate aim to improve survival in patients with solid cancers as VTE is the second leading cause of death in cancer patients. We undertook a systematic review and meta- analysis of randomized controlled trials (RCTs) to determine the impact of PATP with LMWHs on overall survival (OS) in patients with locally advanced or metastatic LC. Methods: We performed a comprehensive literature search using MEDLINE and EMBASE databases through July 26, 2019. The references of all potential studies were also reviewed for any additional relevant studies. RCTs utilizing PATP with LMWHs in patients with locally advanced or metastatic lung cancer were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for progression or metastasis free survival and OS with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q -statistic. Random effects model was applied. Results: A total of 3,452 patients with lung cancer from six RCTs were included in our meta-analysis. The prophylactic doses of bemiparin, dalteparin, tinzaparin, nadroparin and intermediate dose of enoxaparin were used in the studies. The duration of LMWH ranged from 3 to 6 months. The randomization ratio was 1 to 1 in all studies. The I2statistic for heterogeneity was 64, suggesting moderate heterogeneity among RCTs. The pooled HR for OS was not statistically significant at 1.02 (95% CI: 0.83-1.26; P = 0.83). In a subset of small cell lung cancer (SCLC) patients, the pooled HR for OS was 1.03 (95% CI: 0.72-1.48; P = 0.85). The HR for OS was noted at 1.70 (95% CI: 0.70-4.15; P = 0.24) in patients with limited stage SCLC. In a subset of non-small cell lung cancer, the pooled HR of OS was 1.00 (95% CI: 0.79-1.26; P = 0.98). The pooled HR for progression or metastasis free survivalwas 1.03 (95% CI: 0.86-1.24; P = 0.74) according to an analysis of 5 RCTs. Conclusions: Our meta- analysis demonstrated that no survival advantage was noted with the addition of PATP with LMWHs to routine standard chemotherapy in patients with locally advanced or metastatic LC, regardless of histology types as well as stages of SCLC. Disclosures Oo: Medical Education Speakers Network: Honoraria; Janssen and Janssen: Other: Research: site co-investigator .
- Published
- 2019
31. Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails
- Author
-
Arunee Motes, Nuvneet Khandelwal, Nusrat Jahan, Sariya Wongsaengsak, Alay Tikue, Lukman Tijani, Kyaw Zin Thein, and Somedeb Ball
- Subjects
Rivaroxaban ,medicine.medical_specialty ,education.field_of_study ,medicine.drug_class ,business.industry ,Standard treatment ,Immunology ,Population ,Low molecular weight heparin ,Cell Biology ,Hematology ,Biochemistry ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,chemistry ,law ,Edoxaban ,Internal medicine ,Meta-analysis ,medicine ,Apixaban ,education ,business ,medicine.drug - Abstract
Introduction: Cancer patients have approximately 4 times higher risk of developing venous thromboembolism (VTE) compared to the general population. High tendency of bleeding from anticoagulant use in this population makes the treatment of cancer-associated thromboembolism (CAT) very challenging. Low molecular weight heparin (LMWH) is still considered as standard treatment for CAT. Direct oral anticoagulants (DOAC) have emerged as a potential alternative for LMWH due to the ease of administration and predictable pharmacokinetics, but data on DOACs in CAT is limited. Few randomized controlled trials (RCT) published recently have compared the efficacy and safety of DOACs with LMWH in the treatment of CAT. Hence, we conducted an updated meta-analysis of RCTs to determine the relative risk of recurrent VTE and bleeding complications associated with DOACs compared to LMWH in the treatment of thromboembolism in patients with cancer, and to evaluate if the risk estimates have changed since prior report (Li et al.). Methods: We performed a systemic search using Embase, Medline, and the meeting abstracts with appropriate keywords through 06/30/19, to find all RCTs comparing a DOAC with LMWH in treatment of patients with CAT. The search strategy, study selection, data extraction and analysis were performed in accordance with the Preferred Reporting Items for Meta-Analyses (PRISMA) guidelines. We pooled the point estimates in form of risk ratios (RR) with respective 95% confidence intervals (CI), using the random effects model (Mantel-Haenszel method) of Der Simonian and Laird. Heterogeneity of effect size across studies was quantified using I2 statistic and Cochran's Q. Publication bias was assessed by the Egger's regression test. All the statistical analyses were performed with the RevMan 5.3 software. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014. Results: Overall a total of 1,739 patients with CAT (870 in the DOAC arms and 869 in LMWH arms) from three RCTs were included in the final analysis. Characteristics of studies included in the analysis are summarized in table 1. Different DOACs (Select-D: rivaroxaban, Hokusai VTE cancer: edoxaban and ADAM VTE: apixaban) were used to compare with dalteparin in included trials. Duration of anticoagulation was 6 to 12 months in these studies. Use of DOAC was associated with a significantly lower risk of recurrent VTE in comparison with LMWH [pooled RR 0.48, 95%CI: 0.26-0.87, p = 0.02, I2 = 56%, figure 1]. In addition, there was no statistically significant increase in the risk of major bleeding in patients on the DOAC arms, as compared to those on LMWH arms [ pooled RR 1.55 ,95%CI: 0.79-3.04, p = 0.20, I2 = 29%, figure 2]. Criteria for major bleeding in the studies were defined by the International Society on Thrombosis and Hemostasis. The pooled RR for clinically relevant non major bleeding (CRNMB) was 1.80 [95%CI: 0.96-3.38, p = 0.07, I2 = 60%, figure 3], thus suggesting no significant difference in risk of CRNMB between DOAC and LMWH groups. Moderate heterogeneity was noted across trials. We found no publication bias among studies included in the analysis. Conclusion: In our meta-analysis, use of DOACs for the treatment of CAT was associated with a significantly decreased risk of recurrent VTE compared to LMWH. There was no significant difference in the incidence of major or non-major bleeding events between DOAC and LMWH groups. These study results provide additional evidence for potential use of DOAC as a safe and effective alternative to LMWH for the treatment of thromboembolism in patients with cancer. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
32. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
- Author
-
Donald P. Quick, Thein Hlaing Oo, and Kyaw Zin Thein
- Subjects
Relative risk reduction ,Oncology ,Rivaroxaban ,medicine.medical_specialty ,business.industry ,Immunology ,Cancer ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,law.invention ,Randomized controlled trial ,law ,Pancreatic cancer ,Internal medicine ,Meta-analysis ,Ambulatory ,medicine ,business ,medicine.drug - Abstract
Introduction: Thrombosis is the second leading cause of death in cancer patients and patients with APC are categorized as high-risk of developing venous thromboembolism (VTE). Many trials had failed to demonstrate improvement in survival with PATP. Despite decreasing VTE events, PATP in solid cancer patients is not routinely recommended. We conducted an updated meta- analysis of RCTs to determine the benefit and risk of PATP with low-molecular weight heparins (LMWH) and direct oral anticoagulants (DOAC) in patients with APC receiving chemotherapy. Methods: We performed a comprehensive literature search using MEDLINE and EMBASE databases through June 30, 2019. The references of all potential studies were also reviewed for any additional relevant studies. The RCTs with reduction in VTE as a primary or secondary endpoint and the major bleeding (MB) as a safety outcome were incorporated in the analysis. The primary meta- analytic approach was a random effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Results: A total of 1,013 patients with APC from two RCTs and a subgroup of another three RCTs were included in our meta-analysis. The prophylactic, intermediate and therapeutic doses of LMWH and prophylactic dose of DOAC (rivaroxaban) were used in the studies. The duration of LMWH and DOAC ranged from 3 to 6 months. The randomization ratio was 2 to 1 in PROTECHT study and 1 to 1 in all other studies. The I2statistic for heterogeneity was 60, suggesting some heterogeneity among RCTs. The VTE incidence was 28 (5.43%) in PATP group and 60 (12.07%) in control group with a RR of 0.44 (95% CI: 0.20 to 0.99, P = 0.05) and RD of -0.06 (95% CI: -0.11 to -0.01, P = 0.01). In fixed effects model, the pooled RR was 0.45 (95% CI: 0.29 to 0.70, P = 0.0003) and the absolute RD in VTE was -0.07 (95% CI: -0.10 to -0.03, P = 0.0002) with an estimate of the number needed to treat (NNT) of 15 to prevent one VTE event. MB events were reported in 9 (4.11%) patients in PATP group compared to 7 (3.27%) in control group according to an analysis of 2 RCTs. The pooled relative risk for MB was statistically non-significant at 1.25 (95% CI: 0.47 to 3.31, P = 0.65). Conclusions: In our study, PATP in APC may statistically significantly decrease VTE events, approximately with relative risk reduction of 55% and a NNT of 15, without increasing MB events. Proper selection of patients who are high risk for VTE in outpatient setting is important. More RCTs are required to further define high risk subsets of APC patients receiving chemotherapy who may benefit from PATP. Disclosures Oo: Medical Education Speakers Network: Honoraria; Janssen and Janssen: Other: Research: site co-investigator .
- Published
- 2019
33. Effective Implementation of a Structured Protocol for Facilitation of the Judicious Use of Antibody Test for Diagnosis of Heparin Induced Thrombocytopenia
- Author
-
Khatrina Swarup, Lukman Tijani, Nimesh Adhikari, Anita Sultan, Kyaw Zin Thein, Somedeb Ball, Francis Mogollon Duffo, Shabnam Rehman, Meda Srikala, and Sriman Swarup
- Subjects
Protocol (science) ,biology ,business.industry ,Immunology ,Cell Biology ,Hematology ,Gold standard (test) ,Heparin ,Pharmacology ,medicine.disease ,Biochemistry ,Heparin-induced thrombocytopenia ,biology.protein ,Facilitation ,Medicine ,Antibody ,business ,Platelet factor 4 ,medicine.drug - Abstract
Introduction: Heparin induced thrombocytopenia (HIT) is a serious prothrombotic condition, usually triggered by exposure to heparin products with formation of antibodies to platelet factor 4/ heparin polyanion complexes. Diagnostic algorithm for HIT combines clinical scoring (4T score) with time sensitive screening for HIT antibodies (HIT-ab), while serotonin release assay (SRA) is remains the gold standard for confirmatory diagnosis. The rate of utilization of 4T score was low in our institution, resulting in inappropriate orders for HIT-Ab test and subsequent administration of unnecessary alternative anticoagulation (AC) in patients with false positive results. In this project, we designed a structured HIT diagnostic workflow incorporating 4T score calculation in our electronic medical record (EMR) and replaced particle immunofiltration assay (PIFA) with latex immunoturbidometric assay (LIA) in our laboratory for HIT-Ab screening, with an aim to improve the rate of 4T utilization and accuracy of HIT diagnosis in a cost-efficient manner. Methods: In phase I, we performed a retrospective chart review of all patients with PIFA ordered between March 2017-March 2018. Two investigators independently calculated 4T, collected data on results of HIT-Ab, confirmatory SRA tests, and the duration of alternative AC from each record. Any variations in 4T score were resolved by a senior investigator. In phase II, we implemented a new workflow in the EMR incorporating mandatory calculation of 4T score with every order for HIT-Ab test. Our lab started using LIA in place of PIFA. Charts were reviewed on patients with HIT-Ab orders (LIA) from January-June of 2019. Results: On review of data from phase I, we noted that 4T score was documented in only 5 (0.02%) of 170 patients in whom a PIFA test was ordered. Per investigators assessment, 113 (66.4%) patients had low probability (4T ≤ 3), 47 (27.6%) had intermediate probability (4T 4 or 5), and 10 (5.8%) had a high probability (4T ≥ 6) for a diagnosis of HIT. SRA was ordered in 32 patients, although 17 of them had low probability per investigator assessment. PIFA test came back positive in 26 patients, of whom 16 had corresponding SRA results, and three samples were positive for SRA. PIFA was negative in two patients with confirmed HIT (SRA positive). A total of 19 patients received alternate AC in the first phase, 7 of them had low 4T score per our assessment. In phase II, 69 records were found with available LIA results, showing a relative decrease in HIT-Ab orders compared to earlier phase at the six months mark. Documentation of 4T score has been 100% by ordering physicians, a certain improvement from phase I. Investigator calculated 4T score showed low probability in 33 (47.8%) patients, intermediate probability in 31 (44.9%) patients, high probability in 5 (0.07%) patients. LIA was positive in 7 of the 69 ordered tests, 6 of whom scored high/intermediate in the 4T score. HIT diagnosis was confirmed in 3 of these 7 patients with a positive SRA result. During this period, all the 7 of the eight patients who received alternate AC had a high or intermediate probability for HIT as per 4T. Conclusion: Our study demonstrated that the successful implementation of a structured protocol for HIT diagnosis ensured 100% adherence to the calculation and documentation of 4T score by clinicians, and significantly reduced the number of inappropriate HIT-Ab test orders in our institution. Use of alternate AC was also more consistent with the level of probability for HIT. Table Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
34. Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib
- Author
-
Fred Hardwicke, Lukman Tijani, Sriman Swarup, Thura Win Htut, Nicholas D'Cunha, Pwint Phyu Hlaing, Kyaw Zin Thein, Myat Min Han, Yin Mon Myat, Khaing Khaing Htwe, Anita Sultan, Akshar Dash, Sariya Wongsaengsak, and Donald P. Quick
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Immunology ,Waldenstrom macroglobulinemia ,Atrial fibrillation ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Obinutuzumab ,Prednisone ,Ibrutinib ,Internal medicine ,Medicine ,Mantle cell lymphoma ,Rituximab ,business ,medicine.drug - Abstract
Introduction: Bruton's tyrosine kinase (BTK) is a kinase involved in cellular signaling downstream of the B cell receptor and is involved in B-cell survival and proliferation. Hence, BTK inhibitors have become an attractive therapeutic target for a multitude of B cell malignancies, mainly chronic lymphocytic leukemia. Ibrutinib is an oral potent covalent inhibitor of BTK and hence employed in many hematologic malignancies for BTK inhibition. Yet, the risk of atrial fibrillation and major bleeding remains considerable. We undertook an updated analysis of phase III trials to assess the incidence of atrial fibrillation and major bleeding associated with ibrutinib in this susceptible population. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing ibrutinib in patients with hematologic malignancies that mention atrial fibrillation and major bleeding were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: A total of 3,920 patients with CLL/SLL, mantle-cell lymphoma, Waldenstrom's macroglobulinemia and diffuse large b-cell lymphoma, from 10 phase III RCTs were eligible. Studies compared ibrutinib+ obinutuzumab vs chlorambucil+ obinutuzumab, ibrutinib vs chlorambucil, bendamustine+ rituximab vs ibrutinib vs ibrutinib+ rituximab, ibrutinib+ rituximab vs fludarabine+ cyclophosphamide+ rituximab, ibrutinib vs rituximab, ibrutinib vs ofatumumab, ibrutinib+ bendamustine+ rituximab vs bendamustine+ rituximab, ibrutinib vs temsirolimus, ibrutinib+ rituximab+ cyclophosphamide+ doxorubicin+ vincristine+ prednisone vs rituximab+ cyclophosphamide+ doxorubicin+ vincristine+ prednisone were included in the analysis. The randomization ratio was 2:1 in E1912 study and Huang et al. study and 1:1 in other studies. The I2 statistic for heterogeneity was 32, suggesting some heterogeneity among RCT. The atrial fibrillation incidence was 142 (6.52%) in study group vs 17 (0.97%) in control group. The RR for atrial fibrillation was 5.37 (95% CI: 2.74 - 10.54; P < 0.0001) and RD was 0.06 (95% CI: 0.04 to 0.08; P = < 0.0001). Major bleeding was reported in 50 (2.29%) in ibrutinib arm vs 21 (1.20%) in control arm with the RR of 1.73 (95% CI: 1.03 -2.91; P = 0.04). In a subset of patients with CLL/SLL treated with ibrutinib (n= 2658), atrial fibrillation rate was 6.29% higher in study group compared to control arm (RR, 6.14; 95% CI: 2.49 - 15.14; P < 0.0001) and major bleeding rate was 1.32% higher in ibrutinib arm (RR, 2.16; 95% CI: 1.02 - 4.55; P = 0.04). Conclusions: Our study again demonstrated that ibrutinib increases the risk of atrial fibrillation in patients with hematologic malignancies, significantly with a RR of 5.37. Ibrutinib also contributed to higher risk of major bleeding by 1.73. These results are concordant with our previous findings on ibrutinib and remain persistent. Hence, caution is advised with the use of ibrutinib amongst patients who are predisposed to these conditions. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
35. Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
- Author
-
Ei Moe Phyu, Kyaw Zin Thein, Lukman Tijani, Yin Mon Myat, Donald P. Quick, Myint Aung Win, Nicholas D'Cunha, Sriman Swarup, Nimesh Adhikari, Anita Sultan, Thura Win Htut, Akshar Dash, Myat Min Han, and Sanjay Awasthi
- Subjects
Oncology ,medicine.medical_specialty ,Bortezomib ,business.industry ,Immunology ,Daratumumab ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,law.invention ,Thalidomide ,Tolerability ,Randomized controlled trial ,law ,Meta-analysis ,Internal medicine ,medicine ,business ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Introduction: Multiple myeloma, which accounts for 1% of all cancers, is a hematologic cancer in which clonal plasma-cell proliferation leads to complications and death. Over the recent years, it has shown that the introduction of novel agents, including daratumumab and the incorporation of proteasome inhibitors and immunomodulatory drugs has improved outcomes in patients with multiple myeloma. Daratumumab is a human, CD38-targeting, IgG1κ monoclonal antibody with direct antitumor effects and an immunomodulatory component and has recently shown to improve survival in patients with multiple myeloma. However, there are considerable safety concerns. The purpose of our study is to determine the risk of TD and deaths due to treatment-related adverse events (TRAE) in patients with multiple myeloma treated with daratumumab. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing daratumumab in patients with multiple myeloma were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: Five phase III RCTs with a total of 3,547 patients with multiple myeloma were eligible. Studies compared daratumumab (D) + bortezomib (V) + melphan (M) + prednisone (P) vs VMP, D + lenalidomide (R) + dexamethasone (d) vs Rd, DVd vs Vd, DVd + thalidomide (T) vs VTd and DRd vs Rd. The randomization ratio was 1:1 in all studies. Daratumumab was utilized in relapsed and refractory multiple myeloma in the POLLUX study (n= 564) and the CASTOR study (n= 480) and as first-line treatment for patients with multiple myeloma in the ALCYONE study (n= 700), the CASSIOPEIA study (n= 1085) and the MAIA study (n= 737). The I2 statistic for heterogeneity was 39, suggesting some heterogeneity among RCTs. TD due to TRAE was noted in 120 (6.77%) vs 179 (10.08%) in control group with RR of 0.68 (95% CI: 0.51 -0.91; P = 0.0009) and RD of -0.03 (95% CI: -0.06 to 0.00; P = 0.02). TD due to infection/ pneumonia was reported in 0.95% vs 0.73% in control group (RR, 1.19; 95% CI: 0.42 -3.34; P = 0.75). Treatment-related deaths were 64 (3.61%) in daratumumab arm vs 77 (4.34%) in control arm. The pooled RR was not statistically significant at 0.86 (95% CI: 0.59 -1.25; P = 0.43). Conclusions: The rate of discontinuation of trial treatment due to adverse events was significantly lower in the daratumumab group (6.77%) than in the control arm (10.08%) with RR of 0.68, favoring daratumumab combination regimen. Furthermore, there was no significant difference in the treatment discontinuation due to pneumonia or infection and treatment-related deaths due to TRAE in the daratumumab group, compared to control arm. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
36. Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials
- Author
-
Ye Aung, Thura Win Htut, Fred Hardwicke, Sriman Swarup, Nicholas D'Cunha, Nimesh Adhikari, Kyaw Zin Thein, Pwint Phyu Hlaing, Lukman Tijani, Yin Mon Myat, Donald P. Quick, Anita Sultan, Myat Min Han, and Upama Sharma
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Lymphoproliferative disorders ,Cell Biology ,Hematology ,medicine.disease ,Ofatumumab ,Biochemistry ,Small cell lymphoma ,Lymphocytic lymphoma ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,chemistry ,law ,Internal medicine ,Ibrutinib ,medicine ,Rituximab ,Refractory Chronic Lymphocytic Leukemia ,business ,medicine.drug - Abstract
Introduction: The B-cell receptor signaling pathway involves in the pathogenesis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/ SLL), the most common adult lymphoproliferative disorder in western countries. Ibrutinib, a novel Bruton's tyrosine kinase (BTK) inhibitor, has shown great efficacy in the treatment of hematological malignancies via inhibition of BTK, a kinase involved in cellular signaling downstream of the B-cell receptor. However, treatment becomes more challenging upon progression after initial treatment. We performed a combined analysis of currently available randomized controlled trials (RCTs) to evaluate the efficacy of ibrutinib in relapsed or refractory CLL/SLL. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing ibrutinib in patients with previously treated, relapsed or refractory CLL/SLL were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for progression-free survival (PFS) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q -statistic. Random effects model was applied. Results: Three phase III RCTs (HELIOS, RESONATE and Huang et al. studies) with a total of 1,129 patients with relapsed or refractory CLL/SLL were eligible. Studies compared ibrutinib vs ofatumumab, ibrutinib vs rituximab, and ibrutinib+ bendamustine+ rituximab vs bendamustine+ rituximab were included in the analysis. The randomization ratio was 2:1 in Huang et al. study and 1:1 in other studies. The I2 statistic for heterogeneity was 49, suggesting some heterogeneity among RCT. The pooled HR for PFS was statistically significant at 0.17 (95% CI: 0.12-0.22; P < 0.0001). The PFS benefit was observed in all Rai stages, either del11q or del17p status and bulky disease (≥ 5cm); Rai stage ≤ 2 cohort (HR, 0.14; 95% CI: 0.09- 0.22; P < 0.0001), Rai stage >2 cohort (HR, 0.26; 95% CI: 0.19- 0.36; P < 0.0001), del11q group (HR, 0.10; 95% CI: 0.06- 0.17; P < 0.0001), del17p group (HR, 0.24; 95% CI: 0.14- 0.39; P < 0.0001), and bulky disease cohort (HR, 0.19; 95% CI: 0.15- 0.25; P < 0.0001). Conclusions: Our study depicted that ibrutinib maintains activity in previously treated, relapsed or refractory CLL/SLL, across all Rai stages, in bulky disease and in del11q or del17p. Thus, the use of ibrutinib is likely beneficial to patients with relapsed or refractory CLL/SLL, regardless of disease stage, bulkiness or del11q/del 17p status. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
37. Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials
- Author
-
Myat Min Han, Anita Sultan, Jonathan Kopel, Chandler Graf, Donald P. Quick, Sriman Swarup, Nicholas D'Cunha, Yin Mon Myat, Lukman Tijani, Thura Win Htut, Nimesh Adhikari, Kyaw Zin Thein, and Sanjay Awasthi
- Subjects
Oncology ,Bendamustine ,medicine.medical_specialty ,Chlorambucil ,business.industry ,Chronic lymphocytic leukemia ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Fludarabine ,chemistry.chemical_compound ,chemistry ,Obinutuzumab ,hemic and lymphatic diseases ,Ibrutinib ,Internal medicine ,medicine ,Rituximab ,business ,IGHV@ ,medicine.drug - Abstract
Introduction: Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), the most common adult lymphoproliferative disorder in western countries, is a B-cell malignancy that is treated based on presenting symptoms and stage. The treatment response is highly variable depending on disease stage and mutation profile of the malignant B cells. Bruton tyrosine kinase (BTK) is a downstream B-cell signaling kinase that has been shown to play a major role in B cell survival and proliferation. Hence, BTK inhibitors have become an attractive therapeutic strategy for treatment of CLL/SLL in both newly diagnosed and relapse/refractory setting. Ibrutinib is a potent oral, covalent inhibitor of BTK that has gained wide acceptance in treatment of CLL/SLL. We analyzed phase III trials where ibrutinib was used in newly diagnosed untreated CLL/SLL to examine treatment effects based on disease staging and molecular profiling. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing ibrutinib in patients with newly diagnosed/ untreated CLL/SLL were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for progression-free survival (PFS) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q -statistic. Random effects model was applied. Results: Four phase III RCTs (RESONATE-2, iLLUMINATE, E1912 and A041202 studies) with a total of 1,574 patients with newly diagnosed CLL/SLL were eligible. Studies compared ibrutinib+ obinutuzumab vs chlorambucil+ obinutuzumab, ibrutinib vs chlorambucil, bendamustine+ rituximab vs ibrutinib vs ibrutinib+ rituximab, ibrutinib+ rituximab vs fludarabine+ cyclophosphamide+ rituximab, were included in the analysis. The randomization ratio was 2:1 in E1912 study and 1:1 in other studies. The I2 statistic for heterogeneity was 75, suggesting moderate heterogeneity among RCT. The pooled HR for PFS was statistically significant at 0.28 (95% CI: 0.19-0.41; P < 0.0001). The PFS benefit was observed in all Rai stages, either del11q or del17p and unmutated or mutated IGHV status; Rai stage ≤ 2 cohort (HR, 0.29; 95% CI: 0.21- 0.41; P < 0.0001), Rai stage >2 cohort (HR, 0.31; 95% CI: 0.21- 0.46; P < 0.0001), either del11q or del17p cohort (HR, 0.19; 95% CI: 0.12- 0.31; P < 0.0001), unmutated IGHV cohort (HR, 0.18; 95% CI: 0.12- 0.27; P < 0.0001), and mutated IGHV cohort (HR, 0.27; 95% CI: 0.15- 0.49; P < 0.0001). Conclusions: Our meta-analysis showed that ibrutinib maintains activity in newly diagnosed untreated CLL/SLL, across all Rai stages, in del11q or del17p and in unmutated and mutated IGHV. The use of ibrutinib should be further explored considering other factors such as overall survival rates, detrimental side effects, and health-related quality of life for the patients. Ibrutinib clearly outlines an effective treatment option, ultimately increasing the quality of care. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
38. Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib
- Author
-
Myat Min Han, Yin Mon Myat, Ye Aung, Anita Sultan, Jonathan Kopel, Akshar Dash, Lukman Tijani, Thura Win Htut, Kyaw Zin Thein, Myint Aung Win, Nicholas D'Cunha, Donald P. Quick, Ei Moe Phyu, and Sriman Swarup
- Subjects
Bendamustine ,Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Ofatumumab ,Biochemistry ,Duvelisib ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Rituximab ,Refractory Chronic Lymphocytic Leukemia ,business ,Idelalisib ,Adverse effect ,Febrile neutropenia ,medicine.drug - Abstract
Introduction: Idelalisib is a first-in-class potent, oral, selective small-molecule inhibitor of δ isoform of phosphatidylinositol 3-kinase (PI3Kδ), which involves in the signaling of B-cell receptor pathways via activation of downstream serine threonine kinases AKT and mammalian target of rapamycin (mTOR), and has been implicated in the pathogenesis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL). Yet, there are considerable safety concerns. We undertook a systematic review and combined analysis of phase 3 randomized controlled trials to determine the risk of serious adverse events, infection and sepsis in patients with relapsed/ refractory CLL/SLL treated with idelalisib. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase 3 RCTs utilizing idelalisib in patients with relapsed and refractory CLL/SLL that mention serious adverse events, infection and sepsis as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: Three phase 3 RCTs with a total of 892 patients with relapsed and refractory CLL/SLL were eligible for analysis. Studies compared ofatumumab vs idelalisib+ofatumumab, rituximab vs idelalisib+rituximab, bendamustine+ rituximab vs idelalisib+bendamustine+rituximab and ofatumumab vs duvelisib. The randomization ratio was 2:1 in Jones et al. study and 1:1 in other studies. The I2 statistic for heterogeneity was 83, suggesting moderate heterogeneity among RCTs. The incidence of serious adverse events was 341 (69.59%) in study group vs 177 (44.03%) in control group with RR of 1.50 (95% CI: 1.28-1.75; p < 0.0001). Pneumonitis was noted in 14 (2.86%) vs 1 (0.25%) in control group (RR, 5.42; 95% CI: 1.22-24.13; p = 0.03). The incidence of any-grade pneumonia was 78 (15.92%) in study group vs 45 (11.19%) in control group (RR, 1.38; 95% CI: 0.98 - 1.96; P = 0.07). High-grade pneumonia was reported in 59 (12.04%) in idelalisib arm versus 33 (8.21%) in control group with RR of 1.36 (95% CI: 0.82 - 2.27; P = 0.23). Pneumocystis jiroveci (PJP) pneumonia rate was 2.56% higher in study group compared to control arm (RR, 4.25; 95% CI: 1.10 - 16.34; P = 0.04). Febrile neutropenia was noted in 13.47% in study group versus 4.73% in control arm (RR, 2.39; 95% CI: 0.90-6.34; p = 0.08). Sepsis rate was 3.36% higher in idelalisib group compared to control arm and the pooled RR was statistically significant at 2.64 (95% CI 1.10-6.30; p = 0.03). Treatment-related deaths were 45 (6.92%) in idelalisib arm vs 21 (3.74%) in control arm according to analysis of 2 trials. The pooled RR was not statistically significant at 1.64 (95% CI: 0.99 -2.71; P = 0.06). Conclusion: Patients on idelalisib experienced higher risk of serious adverse events, pneumonitis, PJP pneumonia, and sepsis, with RR of 1.50 for serious adverse events, RR of 5.42 for pneumonitis, RR of 4.25 for PJP pneumonia and RR of 2.64 for sepsis respectively. Nevertheless, there was no significant increase in treatment-related deaths due to TRAE in the idelalisib group, compared to control arm. Preemptive measures with proper supportive care are required to reduce those toxicities which can ultimately improve patients' quality of life and may probably affect patients' compliance. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
39. Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy
- Author
-
Lukman Tijani, Thein Hlaing Oo, and Kyaw Zin Thein
- Subjects
Relative risk reduction ,medicine.medical_specialty ,Rivaroxaban ,business.industry ,Immunology ,Absolute risk reduction ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,law.invention ,Randomized controlled trial ,law ,Relative risk ,Internal medicine ,Meta-analysis ,Medicine ,business ,Lung cancer ,medicine.drug - Abstract
Introduction: Lung cancer (LC) is the second most common cancer in both sexes and is the leading cause of cancer mortality in the United States. Thrombosis is the second leading cause of death in cancer patients and PATP in solid cancer patients were performed in research trials to decrease venous thromboembolism (VTE) rates with ultimate aim to improve survival. We undertook an updated meta- analysis of RCTs to determine the benefit and risk of PATP with low-molecular weight heparins (LMWHs) and direct oral anticoagulants (DOAC) in patients with locally advanced or metastatic LC receiving chemotherapy. Methods: We performed a comprehensive literature search using MEDLINE and EMBASE databases through June 30, 2019. The references of all potential studies were also reviewed for any additional relevant studies. The RCTs with reduction in VTE as a primary or secondary endpoint and the major bleeding (MB) as a safety outcome were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Fixed effects model was applied. Results: A total of 5,375 patients with LC from five RCTs and a subgroup of another four RCTs were included in our meta-analysis. The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban were used in the studies. The duration of LMWH and DOAC ranged from 3 to 6 months. The randomization ratio was 2 to 1 in PROTECHT study and 1 to 1 in all other studies. The I2statistic for heterogeneity was 0, suggesting homogeneity among RCTs. The VTE incidence was 114 (4.16%) in PATP group and 207 (7.85%) in control group with a RR of 0.53 (95% CI: 0.43 to 0.67, P < 0.001). The absolute RD in VTE was -0.04 (95% CI: -0.05 to -0.02, P < 0.001) with an estimate of the number needed to treat (NNT) of 28 to prevent one VTE event. MB events were reported in 26 (1.37%) patients in PATP group compared to 15 (0.84%) in control group according to an analysis of 6 RCTs. The pooled relative risk for MB was statistically non-significant at 1.57 (95% CI: 0.85 to 2.88, P = 0.15). Conclusions: Our analysis showed that the relative risk reduction is 46% with a NNT of 28 to prevent one VTE without increasing MB events in ambulatory patients with locally advanced or metastatic LC. Selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from PATP. Disclosures Oo: Janssen and Janssen: Other: Research: site co-investigator ; Medical Education Speakers Network: Honoraria.
- Published
- 2019
40. Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen
- Author
-
Myint Aung Win, Sriman Swarup, Thura Win Htut, Nicholas D'Cunha, Yin Mon Myat, Ei Moe Phyu, Somedeb Ball, Nyein Htway Yu, Anita Sultan, Donald P. Quick, Kyaw Zin Thein, Myat Min Han, Fred Hardwicke, and Sanjay Awasthi
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Immunology ,Biochemistry ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Prednisone ,Internal medicine ,Medicine ,Multiple myeloma ,Lenalidomide ,business.industry ,Bortezomib ,Daratumumab ,Cell Biology ,Hematology ,medicine.disease ,Thalidomide ,Regimen ,030104 developmental biology ,business ,030215 immunology ,medicine.drug - Abstract
Introduction: Proteasome inhibitors-based regimens are the mainstay of initial therapy for most patients with multiple myeloma. Daratumumab is a human IgGκ monoclonal antibody that targets CD38 with direct antitumor effects and has an immunomodulatory component. Recent studies have demonstrated that addition of daratumumab to standard regimens enhance direct cytotoxicity on myeloma cells and have shown survival benefits. Yet, there are notable safety concerns. We performed a combined analysis of randomized controlled trials (RCT) to determine the risk of second primary malignancies (SPM) and peripheral sensory neuropathy (PSN) with newer daratumumab combination regimens. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing daratumumab in patients with multiple myeloma that mention SPM and PSN as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: A total of 3,547 patients with multiple myeloma from 5 phase III RCTs were eligible. Studies compared daratumumab (D) + bortezomib (V) + melphan (M) + prednisone (P) vs VMP, D + lenalidomide (R) + dexamethasone (d) vs Rd, DVd vs Vd and DVd + thalidomide (T) vs VTd. The randomization ratio was 1:1 in all studies. Daratumumab was utilized in relapsed and refractory multiple myeloma in the POLLUX study (n= 564) and the CASTOR study (n= 480) and as first-line treatment for patients with multiple myeloma in the ALCYONE study (n= 700), the CASSIOPEIA study (n= 1085) and the MAIA study (n= 737). The I2 statistic for heterogeneity was 25, suggesting some heterogeneity among RCT. The SPM incidence was 76 (4.29%) in study group vs 77 (4.34%) in control group. The RR for SPM was 1.12 (95% CI: 0.74 - 1.69; P = 0.58) and RD was 0.01 (95% CI: -0.01 to 0.02; P = 0.34). The RR for SPM was noted at 2.56 (95% CI: 0.26 - 25.46; P = 0.42) in a subset of relapsed and refractory multiple myeloma. Any-grade PSN was reported in 527 (46.84%) in daratumumab arm vs 550 (48.72%) in control arm with the RR of 0.98 (95% CI: 0.80 -1.21; P = 0.88). High-grade PSN was noted in 63 (5.6%) vs 76 (6.73%) in control group with the RR of 0.73 (95% CI: 0.42 -1.27; P = 0.27). Conclusions: Our meta-analysis depicted that there was no significant increase in the risk of second primary malignancies and peripheral sensory neuropathy in patients on daratumumab combination regimen, in newly diagnosed and relapsed refractory multiple myeloma, compared to control arm. However, long-term follow-up of these patients is required to determine the actual relation with second primary malignancies. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
41. Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab
- Author
-
Myint Aung Win, Nicholas D'Cunha, Yin Mon Myat, Kyaw Zin Thein, Ei Moe Phyu, Lukman Tijani, Sriman Swarup, Donald P. Quick, Pwint Phyu Hlaing, Thura Win Htut, Fred Hardwicke, Aung M. Tun, Myat Min Han, and Anita Sultan
- Subjects
Oncology ,medicine.medical_specialty ,Bortezomib ,business.industry ,Immunology ,Daratumumab ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,law.invention ,Thalidomide ,Regimen ,Randomized controlled trial ,Prednisone ,law ,Internal medicine ,medicine ,business ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Introduction: Multiple myeloma is a hematologic cancer of plasma cell, a blood cell which normally produce antibodies, and accounts for approximately 13% of all hematologic malignancies. Daratumumab is a human anti CD38 IgGκ monoclonal antibody with a well characterized mechanism of action via direct antitumor effects and an immunomodulatory component and the incorporation of daratumumab to standard multiple myeloma regimen has shown to significantly improve response rates and survival, with notable toxicities. We performed a combined analysis of randomized controlled trials (RCT) to determine the risk of infection and pneumonia in patients with multiple myeloma treated with daratumumab. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing daratumumab in patients with multiple myeloma that mention infection including pneumonia as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: A total of 3,547 patients with multiple myeloma from 5 phase III RCTs were eligible. Studies compared daratumumab (D) + bortezomib (V) + melphan (M) + prednisone (P) vs VMP, D + lenalidomide (R) + dexamethasone (d) vs Rd, DVd vs Vd and DVd + thalidomide (T) vs VTd. The randomization ratio was 1:1 in all studies. Daratumumab was utilized in relapsed and refractory multiple myeloma in the POLLUX study (n= 564) and the CASTOR study (n= 480) and as first-line treatment for patients with multiple myeloma in the ALCYONE study (n= 700), the CASSIOPEIA study (n= 1085) and the MAIA study (n= 737). The I2 statistic for heterogeneity was 35, suggesting some heterogeneity among RCT. The incidence of any-grade infection was 58.01% in study group vs 48.06 % in control group (RR, 1.21; 95% CI: 1.12 - 1.31; P < 0.0001). High-grade infection rate was 5.46% higher in daratumumab group compared to control arm (RR, 1.27; 95% CI: 1.13 - 1.44; P = 0.0001). Any-grade pneumonia was reported in 12.58% in study arm versus 7.72%% in control group with RR of 1.63 (95% CI: 1.08 - 2.45; P = 0.02). High-grade pneumonia was 8.47% in study group versus 5.52% in control arm (RR, 1.51; 95% CI: 0.97 - 2.35; P = 0.07). The RR for high-grade pneumonia was statistically significant at 2.07 (95% CI: 1.50 - 2.85; P < 0.0001) in a subset of newly diagnosed multiple myeloma patients treated with daratumumab (n= 2503). Conclusions: The addition of daratumumab to standard multiple myeloma regimen contributed to higher incidence of all grades of infection and any-grade pneumonia, with RR of 1.27 for high-grade infection and RR of 1.63 for any-grade pneumonia. However, high-grade pneumonia was only found to be significant in a subset of patients with newly diagnosed multiple myeloma treated with daratumumab, with RR of 2.07. Timely intervention with proper supportive care is required. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
42. Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib
- Author
-
Kyaw Zin Thein, Sriman Swarup, Nicholas D'Cunha, Bradley J. Grant, Thura Win Htut, Lukman Tijani, Sanjay Awasthi, Chandler Graf, Donald P. Quick, Fred Hardwicke, Yin Mon Myat, Myat Min Han, Pwint Phyu Hlaing, and Anita Sultan
- Subjects
Bendamustine ,Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Waldenstrom macroglobulinemia ,Cell Biology ,Hematology ,medicine.disease ,Ofatumumab ,Biochemistry ,Fludarabine ,chemistry.chemical_compound ,chemistry ,Obinutuzumab ,hemic and lymphatic diseases ,Internal medicine ,Ibrutinib ,medicine ,Mantle cell lymphoma ,Rituximab ,business ,medicine.drug - Abstract
Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor, has been approved for the treatment of many hematological malignancies including but not limited to, chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and marginal zone lymphoma. Despite the efficacy of this drug in the treatment of hematologic diseases, multiple adverse effects have been well reported. This study seeks to present a combined analysis of currently available randomized controlled trials (RCTs) on the incidence of high-grade hematological toxicities and hypertension, in patients being treated with ibrutinib for hematological malignancies. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing ibrutinib in patients with hematologic malignancies that mention high-grade hematological toxicities and hypertension were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: A total of 3,920 patients with CLL/SLL, mantle-cell lymphoma, Waldenstrom's macroglobulinemia and diffuse large b-cell lymphoma, from 10 phase III RCTs were eligible. Studies compared ibrutinib+ obinutuzumab vs chlorambucil+ obinutuzumab, ibrutinib vs chlorambucil, bendamustine+ rituximab vs ibrutinib vs ibrutinib+ rituximab, ibrutinib+ rituximab vs fludarabine+ cyclophosphamide+ rituximab, ibrutinib vs rituximab, ibrutinib vs ofatumumab, ibrutinib+ bendamustine+ rituximab vs bendamustine+ rituximab, ibrutinib vs temsirolimus, ibrutinib+ rituximab+ cyclophosphamide+ doxorubicin+ vincristine+ prednisone vs rituximab+ cyclophosphamide+ doxorubicin+ vincristine+ prednisone were included in the analysis. The randomization ratio was 2:1 in E1912 study and Huang et al study and 1:1 in other studies. The I2 statistic for heterogeneity was 32, suggesting some heterogeneity among RCT. The RR of high-grade hematologic side effects were as follows: anemia, 0.60 (95% CI: 0.36 - 1.02; p = 0.06); neutropenia, 0.76 (95% CI: 0.55 - 1.05; p = 0.10); thrombocytopenia, 0.69 (95% CI: 0.35 - 1.37; p = 0.29); and febrile neutropenia, 0.65 (95% CI: 0.30 - 1.42; p = 0.29). The incidence of high-grade hypertension (HTN) was 187 (8.59%) in study group vs 40 (2.29%) in control group with RR of 2.51 (95% CI: 1.64 -3.85; P < 0.0001). In a subset of patients with CLL/SLL treated with ibrutinib (n= 2658), the RR of high-grade hematologic side effects were as follows: anemia, 0.51 (95% CI: 0.35 - 0.74; p = 0.0005); neutropenia, 0.73 (95% CI: 0.52 - 1.01; p = 0.06); thrombocytopenia, 0.72 (95% CI: 0.38 - 1.39; p = 0.33); and febrile neutropenia, 0.54 (95% CI: 0.22 - 1.37; p = 0.20). High-grade HTN rate was 8.11% higher in ibrutinib group compared to control arm (RR, 2.49; 95% CI: 1.47 - 4.22; P = 0.0007). Conclusions: This literature review determined that ibrutinib's efficacy must be carefully balanced against the mentioned side effects on a case by case basis. Of special consideration is the rate of HTN in the Ibrutinib group compared to the control. These findings need to be further explored to determine the efficacy of Ibrutinib in specific patient populations with varying underlying diseases. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
43. Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
- Author
-
Anita Sultan, Bradley J. Grant, Donald P. Quick, Chandler Graf, Sriman Swarup, Jonathan Kopel, Thura Win Htut, Somedeb Ball, Ei Moe Phyu, Myat Min Han, Yin Mon Myat, Nicholas D'Cunha, Myint Aung Win, and Kyaw Zin Thein
- Subjects
Kinase ,business.industry ,Immunology ,Lymphoproliferative disorders ,Cell Biology ,Hematology ,Ofatumumab ,medicine.disease ,Biochemistry ,Duvelisib ,chemistry.chemical_compound ,chemistry ,Cancer research ,medicine ,Rituximab ,Phosphatidylinositol ,Refractory Chronic Lymphocytic Leukemia ,Idelalisib ,business ,medicine.drug - Abstract
Introduction: Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/ SLL) is the most common adult lymphoproliferative disorder in western countries and the B-cell receptor signaling pathway has been shown to be involved in the pathogenesis of CLL/ SLL. Phosphatidylinositol 3-kinase (PI3K) is a kinase protein in downstream signaling for multiple pathways in B cells, promoting B-cell survival, proliferation and metabolism. Two prominent PI3K inhibitors, idelalisib (PI3Kδ-selective inhibitor) and duvelisib (PI3Kδ/γ-combinatorial inhibitor), are currently being studied in the treatment of relapsed and refractory CLL/ SLL. The purpose of our study is to explore and consolidate the efficacy of PI3K inhibitors in patients with relapsed and refractory CLL/SLL. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase 3 RCTs utilizing PI3K inhibitors in patients with relapsed and refractory CLL/SLL were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for progression-free survival (PFS) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q -statistic. Random effects model was applied. Results: Four phase 3 RCTs with a total of 1,216 patients with relapsed and refractory CLL/SLL were eligible for analysis. Studies compared ofatumumab vs idelalisib+ofatumumab, rituximab vs idelalisib+rituximab, bendamustine+ rituximab vs idelalisib+bendamustine+rituximab and ofatumumab vs duvelisib. The randomization ratio was 2:1 in the study by Jones et al. and 1:1 in other studies. The I2 statistic for heterogeneity was 82%, suggesting moderate heterogeneity among RCTs. The overall pooled HR for PFS was statistically significant at 0.30 (95% CI: 0.20- 0.47; P < 0.0001). The PFS benefit was observed across all ages and regardless of del 17p or TP53 status; age Conclusions: Our study showed that PI3K inhibitors, idelalisib (PI3Kδ-selective inhibitor) and duvelisib (PI3Kδ/γ-combinatorial inhibitor), significantly improved PFS in patients with relapsed and refractory CLL/ SLL regardless of age and poor prognostic features such as del17p or TP53 and IGHV unmutated status, compared to control arm. The efficacy of these drugs must be balanced against the possible side effects. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
44. Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution Experience
- Author
-
Somedeb Ball, Khatrina Swarup, Sriman Swarup, Sanjay Awasthi, Kyaw Zin Thein, Miguel Quirch, Nimesh Adhikari, Lukman Tijani, and Anita Sultan
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Electronic medical record ,Small sample ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Predictive value ,Internal medicine ,Positive predicative value ,Heparin-induced thrombocytopenia ,medicine ,In patient ,Platelet activation ,Single institution ,business - Abstract
Introduction: Heparin induced thrombocytopenia (HIT) is a severe prothrombotic condition, usually triggered by exposure to heparin products. It is characterized by platelet activation induced by the formation of antibodies to the platelet factor 4 (PF4)/ heparin polyanion complexes. Diagnostic algorithm includes clinical scoring (4T score) alongside serological test for detection of these antibodies (HIT-Ab), while serotonin release assay (SRA) remains the gold- standard for confirmation. The automated latex immunoturbidometric assay (LIA) has recently been FDA approved as a screening tool for HIT and is a potential alternative to the conventional particle immunofiltration assay (PIFA) for time-sensitive detection of HIT-Ab to guide treatment considerations. We recently introduced LIA in our institution. In this study, we present our experience with LIA in comparison to PIFA in the diagnosis of HIT. Methods: We retrospectively reviewed the charts of all the patients on whom a PIFA was ordered between March 2017 and March 2018 in our hospital. We collected information on the results of the PIFA and SRA (if available). We replaced PIFA with LIA for HIT screening. Then, we introduced a structured protocol for diagnosis of HIT in our institution by incorporating 4T scoring alongside LIA order in the electronic medical record (EMR), in December 2018. We reviewed the EMR of all the patients on whom HIT-Ab test (LIA) was ordered between January and June of 2019, and collected similar information as before. All the data were compiled in a single master excel sheet for calculation of performance characteristics (sensitivity, specificity, positive and negative predictive values) for both PIFA and LIA. A patient was considered to have the diagnosis of HIT if the result of SRA was available and positive. Results: In the first phase, a total of 31 orders for SRA was noted against 170 PIFA orders. Five patients had a positive SRA, of whom two were PIFA negative. Half the patients with a negative SRA result were positive for PIFA. Hence, the sensitivity and specificity of PIFA test for our study population were noted to be 60% and 50%, respectively. PIFA had a positive predictive value (PPV) of mere 18.75% for the diagnosis of HIT, whereas the negative predictive value (NPV) was found to be 86.66%. Introduction of structured protocol for HIT diagnosis substantially reduced the number of inappropriate SRA orders in the second phase. On review of data for six months with the new HIT-Ab test LIA, SRA was ordered in only eight patients, to go with 69 orders for the LIA. The result of LIA was positive in all three patients with a positive SRA, whereas it was false positive in four instances. Only one patient was negative for both LIA and SRA during this period. LIA was found to be 100% sensitive and 20% specific for the diagnosis of HIT in our sample. PPV and NPV for LIA were 42.85% and 100%, respectively. Conclusion: The sensitivity and specificity of LIA were found to be 100% and 20%, respectively, in our study population, which is different from the earlier report (Warkentin et al. 2017). The small sample size is a limitation of our study. Higher PPV and NPV for LIA, with its quick turnaround time, make it a useful alternative for the time-sensitive determination of post-test probability for HIT in patients. [HIT- Ab- Heparin Induced Thrombocytopenia Antibody, PIFA- Particle Immunofiltration Assay, LIA- Latex Immunoturbidometric Assay, SRA- Serotonin Release Assay, +ve- Positive, -ve - Negative, PPV- Positive Predictive Value, NPV- Negative Predictive Value] Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
45. Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials
- Author
-
Myint Aung Win, Nicholas D'Cunha, Lukman Tijani, Thura Win Htut, Akshar Dash, Kyaw Zin Thein, Sriman Swarup, Yin Mon Myat, Sanjay Awasthi, Donald P. Quick, Anita Sultan, Myat Min Han, Fred Hardwicke, and Ei Moe Phyu
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Immunology ,Neutropenia ,Biochemistry ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Prednisone ,Internal medicine ,medicine ,Multiple myeloma ,Lenalidomide ,Leukopenia ,business.industry ,Bortezomib ,Daratumumab ,Cell Biology ,Hematology ,medicine.disease ,Thalidomide ,030104 developmental biology ,medicine.symptom ,business ,030215 immunology ,medicine.drug - Abstract
Introduction: Multiple myeloma is a hematologic cancer in which clonal plasma-cell proliferation leads to complications and death. Daratumumab is a humanized IgGκ monoclonal antibody that targets CD38 with direct antitumor effects along with immunomodulatory activity, resulting in depletion of immunosuppressive cells and clonal expansion of cytotoxic T cells. Addition of daratumumab to standard multiple myeloma regimens has recently shown to improve survival in patients with multiple myeloma with considerable safety profile. We undertook a meta- analysis of randomized controlled trials (RCT) to determine the risk of hematological toxicities in patients with multiple myeloma treated with daratumumab. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2019. Phase III RCTs utilizing daratumumab in patients with multiple myeloma that mention hematological toxicities as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran's Q- statistic. Random effects model was applied. Results: A total of 3,547 patients with multiple myeloma from 5 phase III RCTs were eligible. Studies compared daratumumab (D) + bortezomib (V) + melphan (M) + prednisone (P) vs VMP, D + lenalidomide (R) + dexamethasone (d) vs Rd, DVd vs Vd and DVd + thalidomide (T) vs VTd. The randomization ratio was 1:1 in all studies. Daratumumab was utilized in relapsed and refractory multiple myeloma in the POLLUX study (n= 564) and the CASTOR study (n= 480) and as first-line treatment for patients with multiple myeloma in the ALCYONE study (n= 700), the CASSIOPEIA study (n= 1085) and the MAIA study (n= 737). The I2 statistic for heterogeneity was 0, suggesting homogeneity among RCT. The RR of all-grade side effects were as follows: anemia, 0.85 (95% CI: 0.76 - 0.95; p = 0.005); neutropenia, 1.38 (95% CI: 1.09 - 1.74; p = 0.008); thrombocytopenia, 1.15 (95% CI: 0.90 - 1.47; p = 0.27); and leukopenia, 1.60 (95% CI: 1.16 - 2.20; p = 0.004). The RR of high-grade adverse effects were as follows: anemia, 0.72 (95% CI: 0.60 - 0.86; p = 0.0004); neutropenia, 1.48 (95% CI: 1.17 - 1.88; p = 0.001); thrombocytopenia, 1.15 (95% CI: 0.88 - 1.49; p = 0.31); and leukopenia, 1.72 (95% CI: 1.28 - 2.30; p = 0.0003). Conclusions: Our study demonstrated that patients on daratumumab combination regimens experienced higher risk of all grades of neutropenia and leukopenia, with RR of 1.48 and 1.72 for high-grade neutropenia and leukopenia. However, there was lower incidence of all grades of anemia in daratumumab containing group compared to control arm, favoring daratumumab-based regimens. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
46. A Restructured Approach to Diagnosis of Heparin Induced Thrombocytopenia in a Large Tertiary Hospital
- Author
-
Swarup, Sriman, primary, Ball, Somedeb, additional, Adhikari, Nimesh, additional, Welch, Courtney Alice, additional, Fackrell, Jaden, additional, Thein, Kyaw Zin, additional, Sultan, Anita, additional, Swarup, Khatrina, additional, Awasthi, Sanjay, additional, and Tijani, Lukman, additional
- Published
- 2018
- Full Text
- View/download PDF
47. Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis
- Author
-
Myint, Zin W., primary, Shrestha, Runa, additional, Chen, Quan, additional, Huang, Bin, additional, Goldberg, Amit, additional, Ramlal, Reshma, additional, Monohan, Gregory, additional, Fleischman, Roger A., additional, Herzig, Roger H., additional, Hildebrandt, Gerhard Carl, additional, and Saeed, Hayder, additional
- Published
- 2018
- Full Text
- View/download PDF
48. Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis
- Author
-
Quan Chen, Amit Goldberg, Reshma Ramlal, Roger A. Fleischman, Hayder Saeed, Bin Huang, Gerhard C. Hildebrandt, Zin W. Myint, Runa Shrestha, Roger H. Herzig, and Gregory Monohan
- Subjects
Oncology ,medicine.medical_specialty ,Chlorambucil ,business.industry ,Immunology ,Cancer ,Cell Biology ,Hematology ,medicine.disease ,Affect (psychology) ,Biochemistry ,Chemotherapy regimen ,Cancer registry ,Metronidazole ,Internal medicine ,medicine ,Classical Hodgkin lymphoma ,business ,Socioeconomic status ,medicine.drug - Abstract
Introduction: Low socioeconomic status (SES) has been shown to shorten survival in classical Hodgkin lymphoma (cHL). We sought to determine if differences in outcome of cHL varied according to SES and geographic setting in a population-based analysis. Methods: All adult patients diagnosed in 2000-2014 with cHL were collected through Kentucky Cancer Registry (KCR). Baseline SES and clinical variables were collected. Pearson Chi-square, log-rank, and cox regression tests were utilized. To minimize selection bias, cases with less than 6 months survival after cancer diagnosis were excluded. Results: A total of 1075 cHL patients were included, of which 605 (56.3%) were early stage vs. 405 (37.7%) were advanced stage. Most patients were under age 50 (63.2%) with a male predominance (55.4%). Nodular sclerosis was the most common histology (57.6%). Therapy consisted of chemotherapy alone in 729 (67.8%) patients, while 222 (20.7%) had received both chemotherapy and radiation. 633 (58.8%) lived in metro areas. Metro-area residents were more likely to come from non-Appalachian counties (93.7%), have more advanced education (76.8%) and have private insurance (60.1%) than non-metro-area residents (41.2%) (p Conclusion: Our study shows that despite the absence of differences in presenting clinical variables based on SES or geographic setting, significant discrepancies in outcome are observed. This disparity in outcomes may have been affected by differences in access to or quality of care delivery and may widen with the introduction of more costly novel interventions. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
49. Vitamin B12 Deficiency-Related Pseudo-Thrombotic Microangiopathy Might be Misdiagnosed and Treated with Plasma Product Therapy: Review of the Literature and Analysis of the Reported Cases
- Author
-
Tun, Aung M, Myint, Zin W, Rojas Hernandez, Cristhiam, Guevara, Elizabeth, Thein, Kyaw Zin, and Oo, Thein Hlaing
- Published
- 2017
- Full Text
- View/download PDF
50. A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy
- Author
-
Thein, Kyaw Zin, primary, Yeung, Sai-Ching J, additional, and Oo, Thein H., additional
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.